TNF-alpha antagonist therapy modify the tuberculin skin test response (TST). Tumour necrosis factor-alpha (TNF-α) antagonist drugs have been associated with increased risk of tuberculosis (TB). Increased TST responses in patients receiving TNF-α antagonists may be associated with the restoration of suppressed immune reactivity against TB antigens with the decreased disease activity. Tulin Cagatay. (SpringerLink) Rheumatology International. 27 March 2010. (Also see: TNF Inhibitors and Tuberculosis and Scleroderma)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
TNF-alpha antagonist therapy modify the tuberculin skin test response (TST)
No replies to this topic